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Abstract
CCN2 is encoded by an immediate-early gene induced in
mesenchymal cells during the formation of blood vessels, bone
and connective tissue. It plays key roles in cell adhesion and
migration, as well as matrix remodeling. CCN2 is overexpressed
in fibrosis, arthritis and cancer; thus, an understanding of how to
control CCN2 expression is likely to have importance in
developing therapies to combat these pathologies. Previously,
we found that the promoter sequence GAGGAATG is important
for Ccn2 gene regulation in NIH 3T3 fibroblasts. In this report,
we show that this sequence mediates activation of the CCN2
promoter by the ETS family of transcription factors. Endogenous
Ets-1 binds this element of the CCN2 promoter, and dominant
negative Ets-1 and specific Ets-1 small interfering RNA block
induction of CCN2 expression by TGFβ. In the absence of
added TGFβ1, Ets-1, but not the related fli-1, synergizes with
Smad 3 to activate the CCN2 promoter. Whereas the ability of
transfected Ets-1 to activate the CCN2 promoter is dependent
on protein kinase C (PKC), Ets-1 in the presence of co-
transfected Smad3 does not require PKC, suggesting that the
presence of Smad3 bypasses the requirement of Ets-1 for PKC
to activate target promoter activity. Our results are consistent
with the notion that Smad3 and Ets-1 cooperate in the induction
of the CCN2 promoter by TGFβ1. Antagonizing Ets-1 might be
of benefit in attenuating CCN2 expression in fibrosis, arthritis
and cancer, and may be useful in modulating the outcome of
these disorders.
Introduction
CCN2 (connective tissue growth factor) is a member of the
CCN family of matricellular proteins that share a similar pre-
dicted structure [1]. It is thought to comprise four protein mod-
ules sharing identity with insulin-like growth factor binding
proteins, Von Willebrand factor, thrombospondin, and a
cysteine knot-containing family of growth regulators [2].
CCN2 is a secreted protein [3] and as such promotes cell
migration, angiogenesis and fibrotic responses in vivo and in
vitro [2] through a unique integrin- and heparin sulfate prote-
oglycan-dependent mechanism [4,5]. CCN2 is expressed in
mesenchymal cells during development, and mice possessing
a deleted Ccn2 gene die soon after birth due to an inability to
breathe caused by a failure in rib cage ossification, angiogen-
esis and matrix remodeling [6]. Embryonic fibroblasts cultured
from CCN2-deficient animals show reduced signaling
responses to adhesion and impaired stress fiber formation on
fibronectin, suggesting that a physiological role of CCN2 is to
potentiate interaction of cells with matrix [5]. Indeed, a princi-
pal, if not primary, role of CCN2 is to modulate adhesive sign-
aling [3-5]. Consistent with a role for CCN2 in tissue formation
and remodeling, CCN2 is induced during angiogenesis,
wound healing and tissue repair [6], and is constitutively over-
expressed in cancer, atherosclerosis, arthritis and fibrosis
[2,6]. Gaining insight into how CCN2 expression is controlled
is likely to improve the understanding of the molecular basis of
these pathological conditions, as well as to identify potential
new avenues for therapeutic interventions for these disorders.
The cell type in which CCN2 expression has been most exten-
sively studied is the fibroblast. The potent pro-fibrotic protein
transforming growth factor (TGF)β induces CCN2 expression
in dermal fibroblasts, but not in dermal keratinocytes [7-9].
TGFβ induction of CCN2 mRNA in fibroblasts occurs in an
immediate-early fashion, within 30 minutes of TGFβ treatment
[7,8]. This induction requires Smad3, protein kinase C (PKC)
and ras/MEK/ERK [9-11]. In fibroblasts, the TGFβ-mediated
induction of CCN2 is antagonized by AP-1/JNK, suggesting
DMEM = Dulbecco's modified Eagle's medium; PKC = protein kinase C; SEAP = secreted enhanced alkaline phosphatase; siRNA = small interfering 
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that a balance between MEK/ERK and JNK activation is impor-
tant in controlling CCN2 expression [9]. The induction of the
CCN2 promoter also requires a tandem repeat of the nucle-
otides GAGGAATGG, which binds factors enriched in fibrob-
lasts relative to keratinocytes, suggesting that this element
controls the cell type-restricted response of the CCN2 pro-
moter to TGFβ [9]. This element has previously been identified
and mapped using extensive point mutational analysis [9].
However, the identities of the factors binding this element
have not been elucidated, nor has the potential for control of
CCN2 expression by different transcription factors interacting
with this element been clarified.
Ets proteins, which bind the promoter element GGAA/T, are a
large family of transcription factors of which several members
are expressed in a tissue- and cell type-restricted fashion
[12,13]. Because of this diversity, multiple Ets factors may be
able to control the same target genes, albeit to different out-
comes. In addition, functional antagonism between different
Ets factors and between Ets and other transcription factors
has been observed and the combination of Ets proteins and
their coactivators expressed in a particular cell type is likely to
contribute to the cell-type expression of target genes in normal
and pathological states, resulting in distinct pathological con-
sequences. Ets family members regulate the expression of
several genes encoding extracellular matrix and adhesive pro-
teins as well as enzymes involved in matrix degradation
[12,13]. Upon tissue injury, Ets-1 activity is transiently induced
in endothelial cells, smooth muscle cells and fibroblasts during
the early stages of tissue remodeling (for example, in the early
phase of ulcer healing) or immediately after mechanical injury
of the vessel wall [14]. Although Ets-1 DNA binding activity is
increased in scleroderma fibroblasts [15], the Ets family mem-
ber Fli-1 has reduced expression in this cell type [16]; how-
ever, the consequences of altering the Ets-1/Fli-1 ratios on
mesenchymal biology has yet to be fully appreciated. Ets-1 is
overexpressed in synovial fibroblasts from arthritis patients
[17] and is induced during physiological and pathological ang-
iogenesis [13]. The precise target genes, and physiological
effect, of Ets family members in remodeling and repair of con-
nective tissue and associated pathologies is still under much
scrutiny.
In this study, we evaluate the hypothesis that the expression of
CCN2 can be regulated through the activity of Ets-1. Our
results reveal new insights into the control of CCN2 expres-
sion in fibroblasts, and the role of Ets-1 in fibroblast biology.
Our results have implications for the function of CCN2 in phys-
iological tissue repair and in pathologies of the extracellular
matrix.
Materials and methods
Cell culture, transfections and DNA constructs
NIH 3T3 fibroblasts were purchased (ATCC Manassas, VA,
USA) and cultured in DMEM, 10% calf serum penicillin/strep-
tomycin (Invitrogen, Carlsbad, CA, USA) as described by the
supplier. Cells were transfected using polyfect (QiagenValen-
cia, CA, USA) as described by the manufacturer and as previ-
ously described [9,10,18,19]. Briefly, NIH 3T3 cells (3 × 105
cells/well) were placed into 6-well plates. The next day, cells
were transfected with CCN2 promoter/secreted enhanced
alkaline phosphatase (SEAP) reporter expression vectors (0.5
µg DNA/well) as previously described [9,10,18,19]. Pro-
moter/reporter constructs contained CCN2 promoter frag-
ments spanning nucleotides -805 to +17 (-805), -244 to +17
(-244) and -86 to +17 (-86). In addition, CCN2 promoter con-
structs used contained mutations in the Smad element
(TCAGA to GGATC) and GGAA (GGAAT to TCCCG) ele-
ment introduced into the CCN2 promoter between nucle-
otides -805 to +17, but were otherwise identical to construct
-805. CCN2 promoter constructs were co-transfected with
expression vectors (1 µg DNA/well) encoding Ets-1 and Fli-1
(Philip Marsden, University of Toronto), dominant negative Ets-
1 (Hiroshi Sato, Kanazawa University) or Smad3 (Joan Mas-
sague, Sloan-Kettering) when appropriate. Cells were also co-
transfected with a control CMV-β-galactosidase vector (0.25
µg/well; Clontech, Palo Alto, CA, USA as an internal transfec-
tion control. Transfection was performed in serum-free DMEM,
and all cells were cultured for an additional 24 hours in DMEM,
0.5% calf serum, followed by a further incubation for 24 hours
in the presence or absence of 4 ng/ml TGFβ1 (R and D Sys-
tems, Minneapolis, MN, USA) or bisindolymaleimide I (10 µM,
Calbiochem, La Jolla, CA USA). Promoter assays were then
performed (Applied Biosystems, Foster City, CA USA).
Reporter (SEAP) expression was adjusted for differences in β-
galactosidase expression and expressed as average ± stand-
ard deviation of at least three replicates and at least two inde-
pendent trials. Representative experiments are shown.
Statistical analysis (p < 0.05) was performed using the Stu-
dent's t test.
Gel shift analysis
Nuclear extracts were prepared using a kit (Pierce, Rockford,
IL, USA) and protein concentration was determined (Bio-Rad,
Hercules, CA, USA). Gel shifts were performed using 5 µg of
nuclear extract as described [9]. A double-stranded annealed
oligomer spanning nucleotides -126 to -77 of the Ccn2 pro-
moter (Sigma-Genosys, St Lois, MO USA) waslabeled with
32P-ATP (New England Nuclear, Montreal, QC, Canada) using
polynucleotide kinase (New England Biolabs Beverley MA
USA). As DNA competitors, 100-fold molar excess of either
unlabeled wild-type probe or oligomers containing either a
consensus Ets or NFκB binding element (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) were used. For antibody com-
petition assays, 1 µl of anti-Ets-1, anti-Fli-1, anti-Sp1 or anti-
Elk-1 antibody (Santa Cruz Biotechnology) was added to the
binding mixture for 1 hour prior to addition of probe. As previ-
ously described [21], all components of the DNA binding reac-
tion were combined and incubated at room temperature, prior
to addition of radiolabeled probe (60,000 cpm/reaction). AfterAvailable online http://arthritis-research.com/content/8/2/R36
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30 minutes of incubation at room temperature, the binding
reaction was subjected to non-denaturing polyacrylamide gel
electrophoresis in 0.5× TBE, 20 mA. Gels were dried, and
subjected to autoradiography to detect protein/DNA com-
plexes, which were quantified using densitometry (Alpha
Innotech, San Leandro, CA, USA).
siRNA, Western blot and immunofluorescence analysis
Human dermal fibroblasts (ATCC) were transfected with
either 50 nM control small interfering RNA (siRNA; cyclophilin,
Dharmacon, Lafayette, CO, USA) or Ets-1 or Fli-1 siRNA
(SMART Pool, Dharmacon) using Dharmafect 1, as described
by the manufacturer. After a 24 hour incubation in serum-free
DMEM, cells were incubated in the presence or absence of 4
ng/ml TGFβ1 for an additional 24 hours. Cell extracts were
subjected to western blot analyses with anti-CCN2, anti-Ets-
1, anti-Fli-1 and anti-β-actin (Sigma, St Louis, MO, USA) anti-
bodies. Cells were also fixed in 4% paraformaldehyde, 15 min-
utes, room temperature, and indirect immunofluorescence
analysis to detect CCN2 was performed using an anti-CCN2
antibody (Santa Cruz Biotechnology) and a Texas Red-conju-
gated secondary antibody (Jackson Immunoresearch, West
Grove, PA, USA) as previously described [3]. Cells were
counterstained with DAPI (1 µg/ml, 10 minutes; Molecular
Probes, Eugene, OR, USA) and images were captured using
a Leica microscope and Q Imaging software (Burnaby, BC,
Canada).
Results
ETS family members activate the CCN2 promoter 
through GAGGAATG
To assess if the CCN2 promoter was responsive to Ets-1, we
transfected NIH 3T3 fibroblasts with a full-length CCN2 pro-
moter/SEAP reporter construct (driven by nucleotides -805 to
+17 of the CCN2 promoter; Figure 1a) in the presence of
either expression vector encoding Ets-1 or empty expression
vector. We found that overexpression of Ets-1 increased activ-
ity of the full-length CCN2 promoter (Figure 1). To map the
Ets-1 response element in the CCN2 promoter, we trans-
fected NIH 3T3 fibroblasts with CCN2 promoter/reporter con-
structs that contained different segments of the CCN2
promoter (Figure 1a). We found that, whereas a SEAP
reporter gene driven by nucleotides -244 to +17 responded to
Ets-1, a construct containing nucleotides -86 to +17 no longer
responded to Ets-1 (Figure 1b, compare -805, -244 and -86).
To further delineate the elements of the CCN2 promoter
required for the CCN2 promoter to respond to Ets-1, we trans-
fected into NIH 3T3 cells CCN2 promoter constructs contain-
ing point mutations within regions of the CCN2 promoter
previously shown to be important for its regulation. We found
that mutation of the Smad element [19] of the CCN2 promoter
did not significantly affect the ability of Ets-1 to activate it (Fig-
ure 1b). Conversely, mutation of the consensus Ets binding
motif GGAA within the transcription enhancing factor (TEF)
binding element GAGGAATG located between -91 to -84,
Figure 1
ETS family members activate the CCN2 promoter ETS family members activate the CCN2 promoter. (a) Schematic diagram of CCN2 promoter constructs used for this study: -805, construct con-
taining -805 to +17 of the CCN promoter; -244, construct containing -244 to +17; -86, construct containing -86 to +17; Smadmut, construct con-
taining mutated Smad element in the context of -805 to +17; GGAAmut, construct containing mutated GGAA element in the context of -805 to +17 
[9,10,18,19]. Characterization of the CCN2 promoter response to (b) Ets-1 or (c) Fli-1. Different CCN2 promoter/reporter constructs, as indicated, 
were transfected into fibroblasts with either empty expression vector or expression vector encoding Ets-1, as described in Materials and methods. 
Fold increase with overexpression of (b) Ets-1 or (c) Fli-1, relative to the activity observed in the presence of empty control expression vector is 
shown. Average ± standard deviation (N = 6) of a representative experiment is shown (p < 0.05; asterisks indicate significantly modified by overex-
pression of transcription factor). Reporter activity was adjusted for differences in transfection efficiencies among samples using a control β-galactos-
idase expression vector.Arthritis Research & Therapy    Vol 8 No 2    Van Beek et al.
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previously shown to be important for basal and TGFβ-induced
CCN2 expression [9], abolished the ability of the CCN2 pro-
moter to respond to Ets-1 (Figure 1b). To extend these results,
we found that the ETS family member Fli-1 could activate the
CCN2 promoter in fibroblasts in a fashion dependent on the
GGAA motif (Figure 1c). With respect to basal CCN2 pro-
moter activity, Fli-1 behaved in a similar fashion to Ets-1 on all
constructs examined and activated a mutant CCN2 promoter
lacking the Smad response element (data not shown). Collec-
tively, these results suggest that ETS family members activate
the CCN2 promoter through a GGAA located within the
CCN2 proximal promoter.
Ets-1, but not Fli-1, potentiates the TGFβ-induction of 
CCN2
Previously, we showed that the sequence GGAA was involved
with the differential ability of the CCN2 promoter to respond
to TGFβ in fibroblasts, but not keratinocytes [9]. In addition, a
specific protein enriched in fibroblast nuclear extracts bound
nucleotides -126 to -77 of the CCN2 promoter and, hence,
was likely to contribute to the fibroblast-specific regulation of
CCN2 [9]. However, the identity of this protein was not deter-
mined in the prior study. To explore the relative contributions
of Ets-1 and Fli-1 to the induction of the CCN2 promoter by
TGFβ, NIH 3T3 fibroblasts were co-transfected with the full-
length CCN2 promoter/SEAP reporter construct and empty
expression vector, or expression vector encoding Ets-1 or Fli-
1. Cells were treated with TGFβ1 (4 ng/ml, 24 h), and relative
CCN2 promoter activities were assessed (Figure 2). As
shown in Figure 1, fibroblasts transfected with Ets-1 or Fli-1
alone showed a significant increase in CCN2 promoter activ-
ity. As anticipated, TGFβ activated the CCN2 promoter. How-
ever, a further increase in CCN2 promoter activity in response
to TGFβ was noted in cells transfected with Ets-1. In contrast,
transfection of fibroblasts with an expression vector encoding
Fli-1 significantly attenuated the response of the CCN2 pro-
moter to TGFβ (Figure 2). Collectively, these results are con-
sistent with the notion that Ets-1 potentiates the TGFβ
activation of the CCN2 promoter, whereas Fli-1 restricts the
activation of the CCN2 promoter to TGFβ1 (Figure 2).
Ets-1 and Smad3 synergize to activate the CCN2 
promoter in a PKC-independent fashion
Previously, we have shown that Smad3 is required for the
TGFβ-induction of CCN2 and that Smad3 activates the
CCN2 promoter [19]. To elucidate the effect of Smad3 on the
ability of Ets-1 and Fli-1 to regulate the CCN promoter, we
next co-transfected the CCN2 promoter/reporter construct
with expression vectors encoding Ets-1 or Fli-1 individually, or
together with an expression vector for Smad3 (Figure 3a). Co-
transfection of either Ets-1, Fli-1 or Smad3 individually mod-
estly activated the CCN2 promoter. However, a marked syner-
gistic activation of the CCN2 promoter was observed in the
presence of both Ets-1 and Smad3. Conversely, such syner-
gistic activation was not found upon co-transfection of Smad
3 with Fli-1, suggesting that the different Ets family members
show differential use of Smad3 as a co-activator.
The ability of Ets-1 to increase target gene expression may
depend on PKC [22], a pathway previously shown to be
involved in CCN2 expression [9,10]. Conversely, Smad3-
dependent expression of CCN2 is independent of PKC [9,10].
To explore the nature of the synergy between Smad3 and Ets-
1 in the activation of the CCN2 promoter, we examined the
effect of pharmacological inhibition of PKC, using the general
PKC inhibitor bisindolylmaleimide I, to affect the ability of Ets-
1, either in the presence or absence of Smad3, to activate the
CCN2 promoter (Figure 3b). As anticipated, inhibition of PKC,
at a concentration generally used in fibroblasts and shown to
be specific for PKC isoforms [9,10,20], significantly reduced
the activation of the CCN2 promoter by Ets-1. Intriguingly, the
synergistic activation of the CCN2 promoter observed when
Smad3 and Ets-1 were overexpressed together was not
blocked by bisindolylmaleimide I, suggesting that the pres-
ence of Smad3 permits Ets-1 to overcome a requirement for
PKC. These results are consistent with the notion that Smads
act to potentiate the activity of basal transcription factors [23],
and suggest that Smad3 enables Ets-1 to overcome a require-
ment for PKC in the activation of target promoters.
Figure 2
Ets-1, but not Fli-1, enhances the ability of transforming growth factor  (TGF)β to induce the CCN2 promoter Ets-1, but not Fli-1, enhances the ability of transforming growth factor 
(TGF)β to induce the CCN2 promoter. A CCN2 promoter/reporter con-
struct driven by nucleotides -805 to +17 of the CCN2 promoter was 
transfected into fibroblasts in the presence or absence of a 24 h treat-
ment with 4 ng/ml TGFβ1, as indicated. Reporters were co-transfected 
with empty expression vector, or expression vectors encoding Ets-1 or 
Fli-1 (0.5 µg expression vector/well) as indicated. Average ± standard 
deviation (N = 6) is shown. Relative promoter expression is shown. 
Whereas addition of Ets-1 potentiates the TGFβ1 induction of CCN2 
promoter activity (*p < 0.05), Fli-1 limits the TGFβ induction of CCN2 
promoter activity relative to the induction of CCN2 promoter activity 
with TGFβ in the presence of co-transfected empty expression vector 
(**p < 0.05). Both Fli-1 and Ets-1, however, activate the CCN2 pro-
moter in the absence of TGFβ1 (#p < 0.05). TGFβ induces the CCN2 
promoter in the absence of overexpressed transcription factor (@p < 
0.05) Average ± standard deviation (N = 6) of a representavtive experi-
ment is shown. Reporter activity was adjusted for differences in trans-
fection efficiencies among samples using a control β-galactosidase 
expression vector.Available online http://arthritis-research.com/content/8/2/R36
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Ets-1 and Fli-1 bind the CCN2 promoter
To further establish the role of Ets-1 in CCN2 gene expres-
sion, we determined if endogenous Ets-1 bound the TEF/Ets
site of the CCN2 promoter. We performed gel shift assays
using nuclear extracts prepared from NIH 3T3 fibroblasts and
labeled oligonucleotide containing nucleotides -126 to -77 of
the CCN2 promoter. Confirming our previous study where we
precisely mapped the nucleotides in this region required for
CCN2 promoter activity and protein binding in a gel shift assay
[9], a specific DNA/protein complex formed whose presence
was abolished by competition with unlabeled probe (Figure 4).
A double-stranded oligomer bearing a consensus ETS binding
element, but not with a consensus NFκB element, competed
for protein binding to the CCN2 promoter (Figure 4). Further-
more, formation of the specific protein-DNA complex was
reduced by pre-incubation of binding mixture for 1 hour with a
specific anti-Ets-1 and anti-Fli-1 antibody, but not anti-Elk-1 or
anti-Sp1 antibodies, prior to addition of probe. Collectively,
our results suggest that Ets-1 and Fli-1 bind between nucle-
otides -126 to -77 of the CCN2 promoter, probably as an oli-
gomer.
Ets-1 is required for TGFβ-induced CCN2 expression
To further investigate the specific contribution of Ets-1 in
mediating the TGFβ induction of the CCN2 promoter, we
assessed whether overexpression of dominant negative Ets-1
could suppress the response of the CCN2 promoter to TGFβ.
We found that, compared to co-transfection of empty expres-
sion vector, co-transfection of expression vector encoding
dominant negative Ets-1 significantly suppressed the ability of
the CCN2 promoter to respond to TGFβ (Figure 5a). Consist-
ent with our previous observations [19], overexpression of
Smad7 caused a reduction in CCN2 promoter activation by
TGFβ confirming the involvement of the Smad pathway in the
TGFβ-induction of CCN2. To further investigate the conse-
quences of eliminating Ets-1 on CCN2 expression, we intro-
duced specific siRNA recognizing Ets-1, Fli-1 or a control
siRNA into fibroblasts and exposed cells to TGFβ for 24 hours.
Western blot analysis revealed that Ets-1 siRNA and Fli-1
siRNA were effective at reducing Ets-1 or Fli-1 protein expres-
sion, respectively (Figure 5b). However, only Ets-1 siRNA was
able to reduce CCN2 expression (Figure 5b). As cellular
CCN2 is readily detected in the Golgi apparatus of mesenchy-
mal cells [3,10] we assessed CCN2 expression using indirect
immunofluorescence analysis with an anti-CCN2 antibody.
Cells transfected with Ets-1 siRNA, but not control siRNA,
showed reduced CCN2 expression in response to TGFβ (Fig-
ure 5c).
Collectively, these data suggest that a functional binding motif
for the ETS family of transcription factors resides in the CCN2
promoter, corresponding to one part of the element of the
Figure 3
Ets-1 synergizes with Smad3 to activate the CCN2 promoter Ets-1 synergizes with Smad3 to activate the CCN2 promoter. (a) Ets-1, but not Fli-1, synergizes with Smad3 to activate the CCN2 promoter. A 
CCN2 promoter/reporter construct driven by nucleotides -805 to +17 of the CCN2 promoter was transfected into fibroblasts in the presence of 
empty expression vector or expression vector encoding Ets-1, Fli-1 or Smad3, as indicated. After a serum starvation step of 24 h, cells were incu-
bated for an additional 24 h in the presence or absence of 4 ng/ml TGFβ1, as indicated. Co-transfection of Ets-1 and Smad3 (*p < 0.05), but not 
co-transfection of Fli-1 and Smad3, significantly potentiates activation of the CCN2 promoter in comparison with transfection of either Ets-1 or Fli-1 
alone. Average ± standard deviation (N = 6) of a representative experiment is shown. Relative expression is shown. (b) Protein kinase C (PKC) is not 
required for Ets-1/Smad3 synergy. Addition of the general PKC inhibitor bisindolylmaleimide I (bis; 10 µM) blocks the ability of Ets-1 to activate the 
CCN2 promoter. Conversely, addition of bisindolylmaleimide I has no effect on the ability of Smad3 to activate the CCN2 promoter, or on the syner-
gistic activation of the CCN2 promoter by both Smad 3 and Ets-1. Thus, the presence of excess Smad 3 allows Ets-1 to overcome a requirement for 
PKC, and permits the activation of the CCN2 promoter in the absence of PKC. Average ± standard deviation (N = 6) is shown. Fold induction by 
Ets-1, Smad3 or Ets-1/Smad3 is shown, relative to empty control expression vector. Reporter activity was adjusted for differences in transfection 
efficiencies among samples using a control β-galactosidase expression vector.Arthritis Research & Therapy    Vol 8 No 2    Van Beek et al.
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CCN2 promoter necessary and sufficient to respond to TGFβ
[9]. However, our results suggest that Ets-1, but not Fli-1, are
required for the ability of the CCN2 promoter to respond to
TGFβ. To our knowledge, this is a novel, functional divergence
within the ETS family, and points to the potential of selective
use of Ets family members for particular cellular responses.
Discussion
CCN2 is induced by TGFβ in adult mesenchymal cells in a
Smad-dependent fashion, but is constitutively overexpressed
in diseases of excessive matrix production and remodeling,
including cancer, fibrosis and arthritis [6]. The expression of
CCN2 can be either dependent or independent of exogenous
TGFβ [6,19,24,25]. Previously, we showed a sequence in the
CCN2 promoter, GAGGAATGG, was required for basal and
TGFβ-induced CCN2 expression [9]. In this report, we identify
that this element responds to the ETS family of transcription
factors, which bind the consensus sequence GGAA [26,27].
The TGFβ response element of the CCN2 promoter has sev-
eral components, including a Smad element and a GAG-
GAATGG element, that together are capable of conferring
TGFβ-responsiveness to a heterologous promoter [9]. Con-
sistent with the notion that the TGFβ-induction of CCN2
requires Smads, TGFβ does not induce CCN2 protein expres-
sion in Smad3-/- embryonic fibroblasts [19]. In this report, we
show that Ets-1 and Smad3, but not Fli-1 and Smad3, coop-
erate to activate the CCN2 promoter in the absence of added
TGFβ, emphasizing the functional significance of Ets-1 and
Smad3 interactions. In addition, we show that Ets-1 is
required for the TGFβ induction of CCN2, as dominant nega-
tive Ets-1 and siRNA recognizing Ets-1 attenuate the ability of
TGFβ to induce the CCN2 promoter activity and protein
expression in fibroblasts. Thus, for the first time, our data iden-
tify a role for ETS family members, and Ets-1, in the regulation
of CCN2 expression.
Smads interact with other transcription factors to form an
active transcriptional complex on promoters [23]. That Smad3
and Ets-1 synergize to activate CCN2 expression suggests
that Smad3 and Ets-1 functionally interact. Indeed, it has been
recently shown that Smad3 and Ets-1 co-immunoprecipitate
and act to form a transcriptionally active complex with the tran-
Figure 4
Ets-1 and Fli-1 bind the CCN2 promoter Ets-1 and Fli-1 bind the CCN2 promoter. A double-stranded oligomer corresponding to the -126 to -77 segment of the CCN2 promoter was used in 
a gel shift assay with NIH 3T3 fibroblast nuclear extract (5 µg) in the presence or absence of 100-fold molar excess of specific competitor corre-
sponding to unlabeled probe (probe), or competitors corresponding to a consensus ETS (ETS) or NFκB binding site, or a 1 h pre-incubation with 
specific anti-Ets-1 antibody (Ets-1), anti-fli-1 (Fli-1), anti-Elk-1 (Elk-1) or anti-Sp1 (Sp1) antibody. Location of the free probe and shifted Ets-1 con-
taining complex (arrow) are indicated. Representative gel shift assays are shown (N = 3).Available online http://arthritis-research.com/content/8/2/R36
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scriptional cofactor p300 [28]. In this latter report, it was
shown that Smad3 and Ets-1 also interact with the basal tran-
scription factor Sp1, and that inhibition of Sp1 with mithramy-
cin blocked the TGFβ induction of tenascin-C [28]. Consistent
with this notion, we have shown that whereas the Sp1 element
of the CCN2 promoter is not necessary for the TGFβ
response element to act as an enhancer when placed in front
of a heterologous promoter [9,25], the Sp1 inhibitor mithramy-
cin blocks the TGFβ-mediated induction of CCN2 protein in
fibroblasts [24]. Our studies using an anti-Sp1 antibody
revealed that Sp1 was not present in the protein complex bind-
ing to the Ets element of the CCN2 promoter, indicating that
chromatin looping is likely to be involved in the interaction
between Ets and Sp1. It is interesting to note that within the
context of the experiments performed in this present study,
transfected Smad3 was able to induce the CCN2 promoter to
greater effect than TGFβ ligand, emphasizing that endog-
enous Smad levels are not likely to be saturating.
The different effects of Ets-1 and Fli-1 on controlling CCN2
promoter activity is intriguing in light of the fact that approxi-
mately 25 human ETS proteins have been identified, all of
which share a highly conserved DNA binding domain that
interacts with the core DNA target GGAA/T [12,13]. It has
Figure 5
Ets-1 is required for the transforming growth factor (TGF)β induction of CCN2 Ets-1 is required for the transforming growth factor (TGF)β induction of CCN2. (a) Dominant negative Ets-1 blocks the TGFβ induction of the CCN2 
promoter. A CCN2 promoter/reporter construct driven by nucleotides -805 to +17 of the CCN2 promoter was transfected into fibroblasts along 
with empty expression vector or expression vector encoding dominant negative Ets-1 or Smad7, as indicated. Following serum starvation for 24 
hours, cells were incubated in the presence or absence of 4 ng/ml TGFβ1 for 24 h, as indicated. Average ± standard deviation (N = 6) is shown (*p 
< 0.05). (b) Small interfering RNA (siRNA) recognizing Ets-1 mRNA suppresses the TGFβ induction of CCN2. Western blot analysis; fibroblasts 
were transfected either with control siRNA or siRNA recognizing Ets-1 or Fli-1 mRNAs. Following a serum starvation step of 24 h, cells were incu-
bated in the presence or absence of a 4 ng/ml TGFβ1 for 24 h, as indicated. Proteins were blotted onto nitrocellulose, Membranes were probed 
with anti-Ets-1, anti-Fli-1 or anti-CCN2 antibodies, as indicated. Values below CCN2 western blot indicate relative amounts of CCN2 protein as 
determined by densitometry relative to actin. (c) siRNA recognizing Ets-1 mRNA suppresses the TGFβ-induction of CCN2. Immunofluorescence 
analysis; fibroblasts were transfected either with control siRNA or siRNA recognizing Ets-1. After a serum starvation step of 24 h, cells were incu-
bated in the presence or absence of 4 ng/ml TGFβ1 for 24 h, as indicated. Cells were then fixed in paraformaldehyde, and CCN2 was detected with 
an anti-CCN2 antibody followed by incubation with an appropriate Texas Red-conjugated secondary antibody (red). Cells were costained with DAPI 
to detect nuclei (blue).Arthritis Research & Therapy    Vol 8 No 2    Van Beek et al.
Page 8 of 9
(page number not for citation purposes)
been hypothesized that the existence of many different ETS
factors suggests that individual Ets members may have unique
roles [12,13]. Subtle differences in target sites or their own
expression in tissues, and differential response to external sig-
nals may contribute to distinct functions, activating or repress-
ing target gene expression – either basally or in response to
growth factors – depending on a constellation of ETS factors
that compete for binding to ETS binding elements [28-38].
Some recent data have shown that ETS family members con-
tribute to the regulation of genes that mediate matrix remode-
ling, cell migration and cancer progression, including those
controlling cell proliferation, adhesion cell survival, invasion,
and signaling [31-38]. Several recent studies have focused in
particular on the potentially divergent roles of Fli-1 and Ets-1
in providing a balance between tissue homeostasis and repair/
remodeling [22,30,34-37]. Consistent with this notion, both
Ets-1 and Fli-1 activate the promoters of matrix metalloprotei-
nases [22,34-37], enzymes involved with degrading matrix
and promoting cell migration. Similarly, Ets-1 activates
tenascin C, an extracellular matrix glycoprotein that promotes
cell migration and angiogenesis [32,33], and CCN2, encoded
by an immediate-early gene that also promotes cell adhesion
and migration and angiogenesis [2,40,41]. Conversely, type I
collagen is induced by Ets-1 but repressed by Fli-1
[30,34,42]. In the current study, the induction of the CCN2
promoter in response to TGFβ is reduced by Fli-1, and dimin-
ished by dominant negative Ets-1, supporting a divergence in
the roles of Ets-1 and Fli-1 in gene regulation. As we observed
for CCN2, TGFβ induction of tenascin-C is potentiated by Ets-
1; however, the TGFβ-induction of type I collagen is impaired
by Ets-1 [30,34,42]. Given that Ets-1 is induced during the
early phases of tissue repair [14,38,39] and is overexpressed
in tumor stroma, [12,13,41], these results, although albeit
using principally promoter-based approaches, collectively
suggest that Ets-1 could bias the fibroblast population
towards a 'pro-migratory' program in that TGFβ and Ets-1
interactions may bias Ets-1 and TGFβ-responsive genes
toward a migratory/adhesive/invasive phenotype. Conversely,
at later stages of repair when Ets-1 levels decrease, the
effects of TGFβ may switch towards matrix rebuilding, with
increased type I collagen resulting in wound closure.
Conclusion
Our investigation into the mechanism underlying the control of
CCN2 regulation in fibroblasts has revealed a role for an ETS
binding element within the CCN2 promoter. In particular, we
show that the transcription factor Ets-1 contributes to the
TGFβ induction of the CCN2 promoter and protein. Ets-1, but
not the related Fli-1, synergize with Smad3 in activating the
CCN2 promoter, suggesting that the CCN2 promoter can be
differentially regulated by different members of the ETS family.
Our results point to the complexity underlying CCN2 expres-
sion, and are consistent with the notion that different ETS fam-
ily members can have distinct influences on gene expression
in fibroblasts. As CCN2 plays roles in connective tissue
pathologies, targeting Ets-1 may be beneficial in alleviating
pathologies of tissue remodeling and repair, including cancer,
arthritis and fibrosis.
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